Summary

The updated safety results of the RADIANT-2 and −3 Trials have demonstrated a favorable benefit-to-risk profile of everolimus for progressive advanced neuroendocrine tumors. The findings are consistent with those of the initial safety analyses and the known safety profile of the drug in patients with cancer.